课题基金 / 基金详情

项目摘要

项目成果

Amy C. Anderson的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Fungal infections have become a significant and increasing cause of severe illness and death. Candida glabrata is emerging as a lethal fungal pathogen, contributing significantly to the mortality already caused by the prevalent pathogen, Candida albicans. Unfortunately, C. glabrata is inherently resistant to several of the available antifungal therapeutics, including amphotericin B and the azole compounds. Therapeutics to treat C. glabrata infections are critically necessary. Furthermore, since systemic fungal infections often proceed rapidly toward death and formal diagnosis requires critical time, an ideal therapeutic would also be a broad spectrum antifungal agent that is also effective against the primary fungal pathogen, C. albicans. Building on previous success to target dihydrofolate reductase (DHFR) in pathogenic organisms, we have synthesized a class of versatile DHFR inhibitors. Several of an initial series of our inhibitors exhibit strong potency against the fungal DHFR enzymes, good selectivity against the mammalian enzyme, good antifungal activity in cultures of the organisms and little appreciable mammalian cell toxicity. We have also crystallized one of our inhibitors bound to C. glabrata DHFR and determined the structure to 1.6 ¿ resolution. In the first aim of this application, we propose to use a structure-guided approach to design and synthesize new analogs that potently and selectively target C. glabrata DHFR. In a second parallel aim, we will determine efficacy of the compounds in cells and animals, elucidate resistance mechanisms and determine structures of resistant enzymes. In a third aim, we will evaluate these inhibitors against C. albicans and determine crystal structures of potent and selective inhibitors with C. albicans DHFR. In a fourth aim, we propose to generate a potent and selective broad spectrum inhibitor that exhibits excellent antifungal activity against both Candida species and maintains a lack of toxicity against mammalian cells.
期刊论文(27)
专著(0)
科研奖励(0)
会议论文
Towards in silico lead optimization: scores from ensembles of protein/ligand conformations reliably correlate with biological activity.
迈向计算机先导化合物优化:蛋白质/配体构象整体的得分与生物活性可靠地相关。
DOI: 10.1002/prot.21201
发表时间: 2007
期刊: Proteins
影响因子: 2.9
作者: [Popov,VeljkoM, Yee,WAtom, Anderson,AmyC]
通讯作者: Anderson,AmyC
DOI: 10.1021/cb200394t
发表时间: 2012-02-17
期刊: ACS CHEMICAL BIOLOGY
影响因子: 4
作者: [Anderson, Amy C.]
通讯作者: Anderson, Amy C.
DOI: 10.1007/978-1-60327-216-2_23
发表时间: 2012
期刊: Methods in molecular biology (Clifton, N.J.)
影响因子: --
作者: [Anderson, Amy C]
通讯作者: Anderson, Amy C
Acetylenic linkers in lead compounds: a study of the stability of the propargyl-linked antifolates.
先导化合物中的乙炔连接体:炔丙基连接的抗叶酸剂的稳定性研究。
DOI: 10.1124/dmd.112.046870
发表时间: 2012
期刊: Drug metabolism and disposition: the biological fate of chemicals
影响因子: --
作者: [Zhou,Wangda, Viswanathan,Kishore, Hill,Dennis, Anderson,AmyC, Wright,DennisL]
通讯作者: Wright,DennisL
15
    Antimetabolites Effective against Resistant Gram-positive Bacteria
    • 批准号:
      8705774
    • 项目类别:
    • 资助金额:
      $55.77万
    • 财政年份:
      2014
    • 负责人:
      Amy C. Anderson
    • 依托单位:
    2014 Drug Resistance Gordon Research Conference
    • 批准号:
      8775077
    • 项目类别:
    • 资助金额:
      $0.6万
    • 财政年份:
      2014
    • 负责人:
      Amy C. Anderson
    • 依托单位:
    Propargyl-linked Antifolates Targeting Klebsiella pneumoniae
    • 批准号:
      8616446
    • 项目类别:
    • 资助金额:
      $56.22万
    • 财政年份:
      2013
    • 负责人:
      Amy C. Anderson
    • 依托单位:
    DIHYDROFOLATE REDUCTASE-THYMIDYLATE SYNTHASE FROM CRYPTOSPORIDIUM HOMINIS
    海外基金